sutimlimab

DRUG2 trials

Sponsors

Sanofi, RECORDATI GROUP

Conditions

Cold Agglutinin DiseaseCold Agglutinin Disease (CAD)Cold Agglutinin Syndrome (CAS)

Phase 3

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

CompletedNCT05132127

SanofiCold Agglutinin Disease

Start: 2021-11-11End: 2022-11-15Updated: 2025-09-15

Unknown Phase

Cold Agglutinin Disease Real World Evidence Registry

Active, not recruitingNCT05791708

RECORDATI GROUPCold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)

Start: 2019-12-12End: 2028-11-02Updated: 2026-04-22

Related Papers

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

Blood2024-11-05

Cold Agglutinin Disease (CAD) Real-World Evidence (CADENCE) Registry: Update to the Study Design of the First International, Prospective CAD Registry

Blood2023-11-021 citations